#Drug Development #CellCarta #Imagene AI

Strengthening Biopharma Innovation: CellCarta and Imagene AI's Expanded Collaboration

In a significant advancement for the biopharmaceutical industry, CellCarta and Imagene AI have announced the expansion of their collaboration aimed at validating and implementing AI-driven biomarker and companion diagnostic (CDx) programs. This partnership is set to streamline the pathway for biopharma companies, ensuring a coordinated approach from initial discovery through to clinical deployment of these innovative solutions.

Transforming Drug Development

The collaboration fuses Imagene AI's groundbreaking assay development and biomarker prediction capabilities with CellCarta's global infrastructure specially designed for companion diagnostics. Together, they provide biopharma companies a comprehensive solution that encompasses every stage of drug development—from biomarker strategy formulation and assay development to regulatory readiness and clinical trial execution.

As an illustration of this collaboration, both companies are currently engaged in projects with two top global pharmaceutical firms. One of these initiatives involves the development of an AI-powered immunohistochemistry (IHC) companion diagnostic program, while the other focuses on leveraging Imagene’s Lung Prediction Panel to identify biomarkers in non-small cell lung cancer (NSCLC).

The Integration of Cutting-Edge Technology

Imagene AI's capabilities include quantitative AI pathology, which evaluates biomarker and target expression at both cellular and subcellular levels. By using advanced techniques such as continuous and spatial scoring and patient stratification, the firm aims to target and improve patient outcomes through sophisticated data analysis. Meanwhile, CellCarta's robust laboratory infrastructure provides necessary support for validating and deploying these AI-driven methodologies on a global scale.

Rapid Clinical Application

The highlight of their merged offerings is the Multi-gene Lung Prediction Panel, which has the capability to predict vital NSCLC biomarkers within minutes directly from routine whole-slide images. This practical application demonstrates the partnership’s objective of significantly enhancing biomarker-driven clinical trials by accelerating patient identification processes while maintaining the comprehensive support needed for larger-scale deployments.